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Streptococcus pneumoniae CS109 and CS111 were isolated in the United States in 1991 and have high levels
of resistance to expanded-spectrum cephalosporins (MICs of 8 and 32 mg of cefotaxime per ml, respectively).
CS109, but not CS111, also showed high-level resistance to penicillin. As both strains expressed the serotype
23F capsule, were very closely related in overall genotype, and possessed identical or closely related mosaic
pbp1a, pbp2x, and pbp2b genes, it is likely that they have arisen from a recent common ancestor. High-level
resistance to expanded-spectrum cephalosporins was entirely due to alterations of penicillin-binding proteins
(PBPs) 1a and 2x, since a mixture of the cloned pbp1a and pbp2x genes from the resistant strains could
transform the susceptible strain R6 to the full level of cephalosporin resistance of the clinical isolates. Both
PBP1a and PBP2x of these strains were more resistant to inhibition by cephalosporins than those of typical
highly penicillin-resistant isolates. The pbp1a genes of CS109 and CS111 were identical in sequence, and the
fourfold difference in their levels of resistance to cephalosporins was due to a Thr-5503Ala substitution at the
residue following the conserved Lys-Ser-Gly motif of PBP2x. This substitution was also the major cause of the
16-fold-lower resistance of CS111 to penicillin. The pbp2x gene of CS111, in an appropriate genetic background,
could provide resistance to 16 mg of cefotaxime per ml but only to 0.12 mg of benzylpenicillin per ml. Removal
of the codon 550 mutation resulted in a pbp2x gene that provided resistance to 4 mg of cefotaxime per ml and
4 mg of benzylpenicillin per ml. The Thr-5503Ala substitution in CS111 therefore appears to provide increased
resistance to expanded-spectrum cephalosporins but a loss of resistance to penicillin.
Penicillin-resistant and multiply antibiotic-resistant pneu-
mococci have been encountered with increasing frequency dur-
ing the last decade (1, 3, 17, 18, 22, 24). Resistance to penicillin
is due to the development of altered forms of some of the
high-Mr penicillin-binding proteins (PBPs) that have decreased
affinity for the antibiotic (8, 13, 34, 37). Penicillin-resistant
isolates show increased resistance to other b-lactam antibiotics
(1, 17). For example, the MICs of the expanded-spectrum
cephalosporins cefotaxime and ceftriaxone for penicillin-resis-
tant pneumococci are usually about equal to or slightly less
than the MIC of benzylpenicillin. Pneumococci with high-level
resistance to expanded-spectrum cephalosporins (MICs of
ceftriaxone and cefotaxime as high as 16 and 32 mg/ml, respec-
tively) have recently been identified in the United States (4, 11,
26, 32). The emergence and likely increase in the incidence of
high-level cephalosporin resistance is of considerable concern,
as it further limits the available options for the therapy of
serious pneumococcal infections.
The altered PBP genes of penicillin-resistant pneumococci
are very different in sequence from those of penicillin-suscep-
tible isolates and are believed to have arisen by interspecies
recombinational events mediated by genetic transformation
(7–9, 20, 23). Altered (mosaic) pbp1a, pbp2x, and pbp2b genes
are invariably found in pneumococci that are resistant to $0.1
mg of benzylpenicillin per ml (8). Genetic analysis using the
cloned pbp1a, pbp2x, and pbp2b genes has shown that high-
level resistance to penicillin (MICs . 8 mg/ml) can result from
alterations of only these three PBPs (2, 8).
We have shown previously that intermediate-level resistance
to expanded-spectrum cephalosporins in a serogroup 6 isolate
of Streptococcus pneumoniae from Spain (MIC, 4 mg of cefo-
taxime per ml) was entirely due to the expression of altered
forms of PBP1a and PBP2x that had decreased affinity for
these antibiotics (28). In this report we analyze two clinical
isolates that have very high resistance to expanded-spectrum
cephalosporins and show that pneumococci for which the MIC
of cefotaxime is at least 32 mg/ml can result from alterations of
only PBP1a and PBP2x. We also identify the key role of a
substitution at the residue following the conserved Lys-Ser-Gly
motif (15) of PBP2x in the different levels of resistance of these
strains to both cephalosporins and penicillins.
MATERIALS AND METHODS
Bacterial strains and growth conditions. S. pneumoniae was routinely grown at
378C in an atmosphere of 95% air–5% CO2 on brain heart infusion agar (Difco,
Detroit, Mich.) with 4,000 U of catalase/ml or on the same agar plus 5%
defibrinated sheep blood (BHI/B). The properties of the pneumococcal strains
are shown in Table 1. The antimicrobial susceptibility profiles of the clinical
isolates were determined by broth microdilution using cation-adjusted Mueller-
Hinton broth (Becton Dickinson Microbiology Systems, Cockeysville, Md.) sup-
plemented with 3 to 5% lysed horse blood as described by the National Com-
mittee for Clinical Laboratory Standards (30).
Transformation. The nonencapsulated, penicillin-susceptible S. pneumoniae
R6 was used as the recipient for genetic transformation and was made competent
in c1y medium as described previously (28). The role of the altered pbp genes in
cephalosporin resistance was analyzed initially by the two-step procedure used
previously (28), in which strain R6 is transformed to intermediate-level cepha-
losporin resistance with the cloned pbp2x gene and the resulting transformant is
transformed to a higher level of resistance with the cloned pbp1a gene. In
subsequent experiments a one-step procedure was used: 0.25-mg amounts of the
cloned pbp1a and pbp2x genes (replicative-form DNA of M13 recombinants
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containing the pbp genes) were mixed and added to 400 ml of competent cells of
strain R6. The bacteria were incubated at 308C for 30 min and, after 2 h at 378C
to allow expression of antibiotic resistance, they were plated on BHI/B contain-
ing twofold-increasing concentrations of ceftriaxone or cefotaxime. The MICs of
b-lactam antibiotics of the resulting transformants were determined as described
previously (28).
Gene fingerprinting. The pbp1a, pbp2x, and pbp2b genes were amplified from
chromosomal DNA by PCR using primers and conditions described previously
(5). The amplified fragments were purified from agarose gels with GeneClean
(Bio 101, Inc., La Jolla, Calif.), digested with HinfI and MseI plus DdeI (for the
pbp1a and pbp2x genes) or HinfI and StyI (for the pbp2b gene), end labelled with
a-32P-deoxynucleoside triphosphate, fractionated on a 6% nondenaturing poly-
acrylamide gel, and autoradiographed, as described previously (5).
DNA sequencing. The pbp1a, pbp2x, and pbp2b genes were amplified from
chromosomal (or plasmid) DNA by PCR with one 59-biotinylated and one
nonbiotinylated primer, as described previously (16). The biotinylated and non-
biotinylated DNA strands were separated with avidin-coated paramagnetic beads
(Dynal UK, Ltd., Wirral, United Kingdom) and were sequenced with a series of
oligonucleotides that prime at intervals on each DNA strand (16).
Site-directed mutagenesis. The pbp2x gene of CS109 was amplified by PCR (5)
using the proofreading UlTma DNA polymerase (Perkin-Elmer, Branchburg,
N.J.) to minimize the introduction of errors. The 2-kb PCR product was trans-
ferred into pALTER-1 and Ser-701 was converted to Gly-701 by using the
oligonucleotide MUT-1 (59-dTTTTCCAGCCATACATGTC-39) and the Al-
tered Sites II in vitro mutagenesis system (Promega, Madison, Wis.) according to
the manufacturer’s protocol. The desired mutants were identified by sequencing.
The entire pbp2x gene of one of the mutants was sequenced to verify that no
additional mutations had occurred and was recloned in M13mp18.
REP-PCR and pulsed-field gel electrophoresis. PCR using repetitive element
primers (REP-PCR) was performed as described by Versalovic et al. (36).
Genomic DNA for pulsed-field gel electrophoresis was prepared in situ in aga-
rose blocks (21), and the equilibrated DNA was digested with SmaI. The frag-
ments were resolved by pulsed-field electrophoresis in 1% agarose (SeaKem
GTG agarose; FMC Bioproducts, Rockland, Maine) in 0.53 Tris-borate-EDTA
buffer for 20 h at 148C at 6 V/cm in a CHEF-DR II system (Bio-Rad Labora-
tories, Hercules, Calif.). The parameters were an initial pulse time of 1 s in-
creased to 20 s.
Multilocus enzyme electrophoresis and ribotyping. Preparation of cytoplasmic
extracts of S. pneumoniae, horizontal starch gel electrophoresis, and enzyme
staining was performed as described previously (25). For ribotyping, genomic
DNA was digested with HindIII and, after electrophoresis on 0.8% agarose gels,
the fragments were transferred to nylon membranes (MagnaGraph; Micro Sep-
arations Inc., Westboro, Maine) and hybridized with end-labelled 16S–23S
rRNA from Escherichia coli (Sigma Chemical Co., St. Louis, Mo.).
Nucleotide sequence accession numbers. The sequences have been submitted
to the EMBL/GenBank data library under the accession numbers Z49094 to
Z49097.
RESULTS
Characteristics of cephalosporin-resistant isolates. The two
isolates analyzed in this study (CS109 and CS111) were sero-
type 23F pneumococci recovered from patients with invasive
disease in Tennessee in 1991. The isolates were very closely
related, as the patterns of DNA fragments obtained by pulsed-
field gel electrophoresis of SmaI-digested chromosomal DNA
were almost identical (Fig. 1). CS109 and CS111 were indis-
tinguishable by REP-PCR and by ribotyping with HindIII, and
when analyzed by multilocus enzyme electrophoresis they dif-
fered at only one of the 20 enzymes that were assayed (a-
naphthyl propionate esterase).
Although CS109 and CS111 strains were serotype 23F, they
did not appear to be closely related to the widespread Spanish
serotype 23F multiresistant clone (27), as the REP-PCR pro-
files (data not shown) and the patterns of SmaI fragments were
very different (Fig. 1). They also differed from the Spanish 23F
clone at 7 of 20 enzyme-encoding loci and in their antibiotic
resistance profiles (Table 1). Isolate CS109 showed high-level
resistance to penicillin, cefotaxime, and ceftriaxone, whereas
isolate CS111 showed only intermediate-level resistance to
penicillin, but very high resistance to cefotaxime and ceftriax-
one. Both isolates were susceptible to chloramphenicol and
tetracycline; CS111 demonstrated low-level resistance to eryth-
romycin.
Mosaic pbp1a, pbp2x, and pbp2b genes in strains CS109 and
CS111. The pbp1a, pbp2x, and pbp2b genes of CS109 and
CS111 were amplified by PCR, and gene fingerprints were
obtained with frequently cutting restriction enzymes (Fig. 2).
With the exception of the pbp2b gene of strain CS111, which
was indistinguishable from that of strain R6, the fingerprints of
all three genes were different from those of penicillin-suscep-
tible pneumococci, suggesting that the pbp1a and pbp2x genes
(and the pbp2b gene of strain CS109) of the resistant isolates
possessed the mosaic structure invariably found in pneumo-
FIG. 1. Pulsed-field gel electrophoresis separation of SmaI restriction frag-
ments of S. pneumoniae strains. Lane A, strain R6; lane B, CS111; lane C, CS109;
lane D, Spanish 23F clone. The sizes of molecular markers (phage l DNA
ladder) are indicated on the left.
TABLE 1. Properties of pneumococcal strainsa
Strain Serotype
MIC (mg/ml) of: Susceptibility to: Yr of
isolation OriginPenG Cefotaxime Ceftriaxone Chlor Tet Ery
R6 NT 0.016 0.016 0.016 S S S 1930s United States
CS109 23F 4 8 4 S S S 1991 United States
CS111 23F 0.25 32 16 S S (R) 1991 United States
Hun159 19A 16 2 2 R R R 1993 Hungary
SP264 23F 1 0.5 0.5 R R S 1989 Spain
SP971 6B 2 0.5 0.5 R R S 1984 Spain
a NT, nonencapsulated strain; S, susceptible; R, resistant; (R), low-level resistant; PenG, penicillin G; Chlor, chloramphenicol; Tet, tetracycline; Ery, erythromycin.
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cocci with intermediate- or high-level resistance to penicillin.
Sequencing of the pbp2b gene of strain CS111 showed that it
also possessed mosaic structure, although this was not detected
by fingerprinting, as the distribution of StyI or HinfI sites was
not altered in relation to that in the pbp2b gene from strain R6.
The pbp1a and pbp2x genes of strains CS109 and CS111 could
not be distinguished by fingerprinting, but their pbp2b genes
were clearly distinct (Fig. 2). The pbp1a and pbp2x gene fin-
gerprints of strains CS109 and CS111 (and the pbp2b gene of
CS109) were different from any in our database of fingerprints
of pbp genes from b-lactam-resistant pneumococci isolated
worldwide.
Role of altered pbp genes in the resistance of strains CS109
and CS111 to expanded-spectrum cephalosporins. The pbp1a
and pbp2x genes of strains CS109 and CS111 were amplified by
PCR and were cloned into M13mp18. Replicative-form DNA
of the resulting phage was used to transform S. pneumoniae R6
to increased levels of resistance to cefotaxime. The pbp2x gene
from either strain was able to transform strain R6 to an inter-
mediate level of cefotaxime resistance (Table 2). Strain R6
could be transformed to a higher level of resistance by using a
mixture of equal amounts of the cloned pbp1a and pbp2x genes.
The MICs of ceftriaxone and cefotaxime for the resulting
transformants (R6CS109/2x/1a and R6CS111/2x/1a) were the same
as those for the resistant clinical isolates from which the pbp
genes were cloned (Table 2 [the genetic nomenclature for
transformants of strain R6 is described in footnote a]). High-
level cephalosporin resistance in CS109 and CS111 was there-
fore entirely due to alterations of PBP2x and PBP1a.
Strain CS111 was fourfold more resistant to cefotaxime and
ceftriaxone than strain CS109. A mixture of equal amounts of
the cloned pbp1a gene of strain CS111 and the cloned pbp2x
gene of strain CS109 was used to transform the susceptible
strain R6 to increased resistance to cefotaxime. The resulting
transformants (R6CS109/2x/CS111/1a) showed the lower level of
cephalosporin resistance characteristic of strain CS109 (Table
2). Conversely, transformants of strain R6 obtained with equal
quantities of the cloned pbp1a gene of strain CS109 and the
cloned pbp2x gene of strain CS111 had the higher level of
cephalosporin resistance characteristic of strain CS111 (Table
2). The higher degree of resistance to cefotaxime and ceftri-
axone of strain CS111 compared with CS109 was therefore due
to a difference in their pbp2x genes rather than their pbp1a
genes.
We next investigated whether the exceptionally high level of
cephalosporin resistance of strain CS111 was due solely to the
production of an altered PBP2x that had extremely low affinity
for cephalosporins or whether it also required an altered
PBP1a with unusually low affinity for cephalosporins. The
cloned pbp1a genes of two typical high-level penicillin-resistant
pneumococci (strains SP971 and SP264, members of the suc-
cessful Spanish serotype 6B [29, 31] and 23F [27] multiresistant
clones, respectively), which have substantial levels of cross-
resistance to expanded-spectrum cephalosporins (Table 1),
were therefore used, together with an equal amount of the
cloned pbp2x gene from strain CS111, to transform strain R6 to
FIG. 2. Fingerprints of the pbp genes of cephalosporin-resistant pneumo-
cocci. The pbp2b gene was digested with StyI (lanes A to C) or HinfI (lanes D to
F). The pbp2x and pbp1a genes were digested with HinfI (lanes A to C) or DdeI
plusMseI (lanes D to F). Lanes A and D, strain R6; lanes B and E, CS109; lanes
C and F, CS111. Lane m, molecular size markers (pBR322 digested with HpaII).
The sizes of the visible pBR322 HpaII fragments are 622, 527, 404, 309, 242, 238,
217, 201, 190, 180, 160, 147, 123, 110, 90, 76, 67, 34, and 26 bp. Slight differences
in the DdeI-MseI fragments from the pbp2x genes of CS109 and CS111 within the
50- to 80-bp region (lanes E and F) were probably gel artifacts, as no differences
were observed in several other experiments.
TABLE 2. Transformants constructed to analyze the role
of PBPs in cephalosporin resistance
Strain or
transformanta
MIC (mg/ml) of:
Cefotaxime Ceftriaxone PenGb
R6 0.016 0.016 0.016
R6CS109/2x 0.5 0.25 0.032
R6CS111/2x 0.5 0.25 0.032
R6CS109/2x/1a 8 4 0.064
R6CS111/2x/1a 32 16 0.064
R6CS109/2x/CS111/1a 8 4 0.064
R6CS111/2x/CS109/1a 32 16 0.064
R6CS111/2x/SP264/1a 2 1 0.064
R6CS111/2x/SP971/1a 2 1 0.064
R6SP264/2x/CS111/1a 1 0.5 0.064
R6SP971/2x/CS111/1a 1 1 0.064
R6ancestral/2x/CS111/1a 8 4 0.064
R6double/2x/CS109/1a 32 16 0.064
a R6CS109/2x/1a corresponds to a transformant of R6 containing the pbp2x and
pbp1a genes of strain CS111. Similarly, R6CS111/2x/CS109/1a contains the pbp2x
gene from CS111 and the pbp1a gene from CS109. The ancestral pbp2x gene
lacking the codon 550 and 701 mutations (ancestral) and the pbp2x gene with
both mutations (double) are described in the text.
b PenG, penicillin G.
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increased resistance to cefotaxime. The maximum level of re-
sistance of the resulting transformants (R6CS111/2x/SP264/1a and
R6CS111/2x/SP971/1a) was 2 mg of cefotaxime per ml (Table 2).
Similarly, transformation of strain R6 with a mixture of the
pbp1a gene from strain CS111 and the pbp2x genes from the
highly penicillin-resistant pneumococci produced transfor-
mants (R6SP264/2x/CS111/1a and R6SP971/2x/CS111/1a) that had a
maximum MIC of 1 mg of cefotaxime per ml (Table 2). Our
results suggest that both PBP2x and PBP1a of strain CS111
have unusually low affinity for expanded-spectrum cephalospo-
rins compared with those of typical highly penicillin-resistant
pneumococci.
Nucleotide sequences of the pbp1a, pbp2x, and pbp2b genes
of strains CS109 and CS111. The pbp1a genes of strains CS109
and CS111 were identical in sequence (data not shown). The
sequence differed from that of the susceptible strain R6 at
11.2% of nucleotide sites, resulting in 56 differences in the
amino acid sequence of PBP1a. There were only 16 nucleotide
differences within the first 938 bp (1.7% divergence) and one
difference within the last 237 bp (0.4% divergence), but the
region between codons 313 and 641 differed at 226 sites (22.9%
divergence).
The pbp2x genes of strains CS109 and CS111 were almost
identical (differing only at two nucleotide sites), but they dif-
fered from the pbp2x gene of strain R6 at 14.4% of nucleotide
sites (Fig. 3). The front part of the gene (codons 84 to 249 [the
first 83 codons were not sequenced]) differed from that of
strain R6 at 3.6% of sites, whereas the remainder of the gene,
including the whole region that encodes the transpeptidase
domain, differed at 18.6% of sites. The two differences be-
tween the pbp2x genes of strains CS109 and CS111 were both
nonsynonymous substitutions, and the PBP2x sequences of the
isolates therefore differed at two amino acid residues (Fig. 4).
Residue 550, immediately following the conserved Lys-Ser-Gly
sequence motif (15), was Ala in PBP2x of strain CS111,
whereas this residue in strain CS109 was the same as that (Thr)
in the penicillin-susceptible strain R6. Conversely, residue 701
in strain CS111 was the same as that (Gly) in strain R6,
whereas there was a Ser at this position in PBP2x from strain
CS109.
The pbp2b gene of CS111 was almost identical to those of
penicillin-susceptible isolates except for the presence of a
20.7%-diverged region from codon 618 to the end of the gene.
The pbp2b gene from CS109 contained the identical down-
stream diverged region but also differed from susceptible
strains by 12.1% between codons 332 and 615 (Fig. 5).
Role of alterations of pbp2x in resistance to cephalosporins.
As the mosaic pbp2x genes of strains CS109 and CS111 were
identical in sequence (except at two positions) but differed
extensively from the pbp2x genes of penicillin-susceptible
pneumococci, it is almost certain that they are derived from the
same ancestral mosaic PBP gene. The most parsimonious ex-
planation is that selection for increased resistance to b-lactam
antibiotics resulted in two different nonsynonymous mutations
in the ancestral mosaic gene, leading to the Gly-7013Ser al-
teration in strain CS109 and the Thr-5503Ala alteration in
strain CS111. The presumed ancestral mosaic gene was there-
fore constructed by converting the Ser-701 codon of the pbp2x
gene of CS109 back to a Gly codon (Fig. 4). Equal amounts of
the cloned pbp1a gene of strain CS111 and the modified pbp2x
gene were used to transform strain R6 to cefotaxime resis-
tance. The MICs of cefotaxime and ceftriaxone for the result-
ing transformants (R6ancestral/2x/CS111/1a) were 8 and 4 mg/ml,
respectively (Table 2; Fig. 4). The ancestral pbp2x gene (when
combined with the pbp1a gene of CS111) therefore provided
high levels of cephalosporin resistance, which were equal to
those of strain CS109 but fourfold less than those of strain
CS111.
We next examined whether PBP2x containing both the Thr-
5503Ala and the Gly-7013Ser substitutions would provide
greater resistance to expanded-spectrum cephalosporins than
that exhibited by strain CS111. The transformant R6CS109/2x/1a
was transformed to a higher level of resistance to cefotaxime
with the cloned pbp2x gene of strain CS111. Recombinational
crossovers that occur upstream of codon 550 and downstream
of codon 701 (regions I and III in Fig. 4) result in transfor-
mants that express PBP2x with Ala-550 and Gly-701 (as in
strain CS111). Alternatively, a crossover upstream of codon
550 combined with one between codons 550 and 701 (regions
I and II in Fig. 4) results in transformants that express PBP2x
containing both Ala-550 and Ser-701 (Fig. 4). Partial sequenc-
ing of the pbp2x genes from six transformants obtained from
agar plates containing 8 mg of cefotaxime per ml (a concen-
tration that prevents the growth of the recipient strain,
R6CS109/2x/1a) showed that five had the desired double substi-
tution (Ala-550 and Ser-701) whereas the other had Ala-550
combined with Gly-701. However, the MICs of cefotaxime and
ceftriaxone (Table 2) for these two classes of transformants
(R6double/2x/CS109/1a) and R6CS111/2x/CS109/1a) were identical (32
mg of cefotaxime and 16 mg of ceftriaxone per ml). The com-
bination of the Thr-5503Ala and Gly-7013Ser alterations did
not therefore provide increased resistance over that afforded
by the PBP2x gene of CS111.
Genetic analysis of penicillin resistance of CS109 and CS111.
The 16-fold-higher level of penicillin resistance of strain
CS109 compared with CS111 could have been due to differ-
ences in their pbp2x and/or pbp2b genes. To analyze the contri-
bution of the differences in pbp2x, R6CS109/2x/1a, R6CS111/2x/1a,
R6ancestor/2x/CS111/1a, and R6double/2x/CS111/1a, which are all sus-
ceptible to penicillin (MICs, 0.064 mg/ml) as they have a nor-
mal high-affinity PBP2b, were transformed to an increased
level of resistance to penicillin with the cloned pbp2b gene
from a clinical isolate with very high resistance to penicillin
(Hun159; MIC, 16 mg/ml; Table 1). As these transformants
express identical low-affinity forms of PBP1a and -2b, any vari-
ation in their MICs of penicillin should be due to differences in
their pbp2x genes. Transformants containing the pbp2x gene of
CS111 (R6CS111/2x/1a/Hun159/2b) had MICs of penicillin of 0.12
mg/ml, whereas those possessing the pbp2x gene of CS109
(R6CS109/2x/1a/Hun159/2b) had MICs of 8 mg/ml (Table 3). Trans-
formants containing the putative ancestral pbp2x gene were as
resistant to penicillin as those containing the pbp2x gene of
CS109 (Table 3). The introduction of the Thr-5503Ala sub-
stitution in PBP2x of CS111, which results in increased resis-
tance to cephalosporins, appears to cause a loss of resistance to
penicillin.
The contribution of the pbp2b gene to the difference in the
penicillin resistance of strains CS109 and CS111 was examined
by transforming R6CS109/2x/1a and R6CS111/2x/1a to increased
penicillin resistance by using the cloned pbp2b genes from CS109
and CS111. As expected from the experiments described
above, transformants of R6CS111/2x/1a obtained with either
pbp2b gene had only low levels of resistance to penicillin (Ta-
ble 3). The MIC of penicillin for transformants of R6CS109/2x/1a
obtained with the pbp2b gene of CS111 was 1 mg/ml, whereas
the MIC for transformants obtained with the pbp2b gene of
CS109 was 4 mg/ml (Table 3). The pbp2b gene of CS109 can
therefore provide higher levels of resistance to penicillin than
that of CS111.
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DISCUSSION
Genetic analysis established that the high level of resistance
of strains CS109 and CS111 to cefotaxime and ceftriaxone was
due to the production of altered low-affinity forms of only
PBP1a and -2x, in contrast to intermediate- or high-level re-
sistance to penicillin (2), which requires reductions in the
affinities of PBP1a, -2x, and -2b. The pbp2b gene of S. pneu-
moniae has very low affinity for cephalosporins, and inactiva-
tion of this PBP appears not to be involved in the killing action
of cefotaxime or ceftriaxone at physiologically relevant con-
centrations (14). Consequently, resistance to expanded-spec-
trum cephalosporins will not necessarily correlate with resis-
tance to penicillins. This is clearly seen with the transformant
R6CS111/2x/1a, for which the MIC of cefotaxime was 32 mg/ml, as
this transformant possesses low-affinity forms of PBP2x and
PBP1a, but the MIC of benzylpenicillin was only 0.064 mg/ml,
FIG. 3. Partial sequences of the pbp2x genes of cephalosporin-resistant pneumococci. The sequence of the pbp2x gene and the amino acid sequence of PBP2x are
shown for strain R6. The nucleotide and amino acid sequences are numbered at the end of each line on the basis of data in reference 19. Positions at which pbp2x
sequences of strains CS109 and CS111 differ from the R6 sequence are shown. Positions at which the PBP2x amino acid sequence of CS109 differs from that of R6
are also shown. The PBP2x amino acid sequence of strain CS111 is identical to that of CS109, except at residues 550 and 701 (doubly underlined). The active-site serine,
Ser-X-Asn, and Lys-Ser-Gly conserved sequence motifs (15, 35) are also doubly underlined.
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as the transformant possesses a normal PBP2b (Table 2). Pre-
sumably, highly cephalosporin-resistant, but penicillin-suscep-
tible, clinical isolates of this type could emerge in nature by the
horizontal transfer of the pbp2x and pbp1a genes from isolates
like CS111 into susceptible pneumococci. As demonstrated
previously (28), horizontal transfer of cephalosporin resistance
can be readily achieved in a single step by transformation using
chromosomal DNA, presumably because the pbp2x and pbp1a
genes are closely linked on the pneumococcal chromosome
(12).
Susceptibility of pneumococci to b-lactam antibiotics is gen-
erally carried out with oxacillin discs. High-level resistance to
oxacillin requires alterations of both PBP2x and PBP2b (10),
and both CS109 and CS111 gave oxacillin diffusion zones of
,20 mm and would be detected as resistant isolates. Highly
cephalosporin-resistant, but penicillin-susceptible, pneumo-
cocci that possess a normal PBP2b (e.g., R6CS111/2x/1a) have
only low-level resistance to oxacillin but should still be recog-
nized as b-lactam resistant with oxacillin discs.
Transformants of the antibiotic-susceptible strain R6, ex-
pressing the pbp2x gene of CS111 and the pbp1a gene of the
multiresistant serotype 6B or 23F Spanish clones of S. pneu-
moniae, or the pbp1a gene of CS111 and the pbp2x gene of the
FIG. 4. Mosaic PBP2x of cephalosporin-resistant pneumococci and transformants. The positions of the active-site serine residue (S), the Ser-X-Asn motif (SXN),
and the Lys-Ser-Gly motif (KSG) are indicated (15, 35). The residues that differ in PBP2x sequences of strains CS109 and CS111 are underlined and italicized in the
diagram of PBP2x of strain R6. The MICs of cefotaxime and benzylpenicillin correspond to the highest levels of resistance that the illustrated PBP2x can provide when
expressed together with PBP1a and/or PBP2b from highly penicillin- or cephalosporin-resistant pneumococci. The MICs of cefotaxime are those of transformants of
strain R6 expressing PBP1a of strain CS111 (or CS109) and the illustrated PBP2x. The MICs of benzylpenicillin are those of transformants of R6 expressing PBP2b
of strain Hun159, PBP1a of strain CS111 (or CS109), and the illustrated PBP2x. CS109/111(A) and CS109/111(B) are the two types of PBP2x resulting from
recombinational crossovers between regions I and III or regions I and II, respectively, of the pbp2x gene (see the text). The sequences of PBP2x of CS109, CS111,
CS109/111(A), and CS109/111(B) are identical except at residues 550 and/or 701, but, as indicated by the stippling, the sequences of their transpeptidase domains differ
extensively from the sequence of PBP2x of strain R6.
FIG. 5. Possible origins of strains CS109 and CS111. PBP1a, -2x, and -2b of
CS109 and CS111 and the presumed common ancestor of these strains are shown
(not to scale). The patterned portions represent parts of the PBPs that are
encoded by regions that are highly diverged from the sequences of the corre-
sponding genes from penicillin-susceptible pneumococci.
TABLE 3. Transformants constructed to analyze the role
of PBPs in penicillin resistance
Transformant
MIC (mg/ml) of:
Cefotaxime Ceftriaxone PenGa
R6CS109/2x/1a 8 4 0.064
R6CS111/2x/1a 32 16 0.064
R6ancestral/2x/CS111/1a 8 4 0.064
R6double/2x/CS111/1a 32 16 0.064
R6CS109/2x/1a/Hun159/2b 8 4 8
R6CS111/2x/1a/Hun159/2b 32 16 0.12
R6ancestral/2x/CS111/1a/Hun159/2b 8 4 8
R6double/2x/CS111/1a/Hun159/2b 32 16 0.25
R6CS109/2x/1a/2b 8 4 4
R6CS111/2x/1a/2b 32 16 0.12
R6CS109/2x/1a/CS111/2b 8 4 1
R6CS111/2x/1a/CS109/2b 32 16 0.25
R6ancestor/2x/CS111/1a/2b 8 4 1
R6ancestor/2x/CS111/1a/CS109/2b 8 4 4
R6double/2x/CS111/1a/CS109/2b 32 16 0.25
R6double/2x/CS111/1a/CS111/2b 32 16 0.12
a PenG, penicillin G.
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serotype 6B or 23F clones, did not show the high levels of
cephalosporin resistance of CS111. The very high level of ceph-
alosporin resistance in strain CS111 appears therefore to be
due to the expression of altered forms of both PBP2x and
PBP1a that have unusually low affinity for cefotaxime and
ceftriaxone, compared with those of typical highly penicillin-
resistant pneumococci. This implies that highly penicillin-re-
sistant pneumococci, such as the successful multiresistant
Spanish 6B (33) or 23F (27) clones, would require alterations
of both PBP1a and PBP2x to achieve the levels of resistance to
expanded-spectrum cephalosporins seen with strains CS109
and CS111. Variants of the Spanish 23F clone that have four-
fold-increased resistance to ceftriaxone and cefotaxime have,
however, recently been detected in the United States (26), and
an analysis of one of these isolates will be presented elsewhere.
The fourfold-greater resistance of CS111 to cefotaxime and
ceftriaxone, compared with CS109, was due to differences in
pbp2x. There were two amino acid differences between PBP2x
of CS109 and PBP2x of CS111, but the higher resistance of
CS111 could be clearly ascribed to the Thr-5503Ala substitu-
tion. This substitution is of particular interest, as it occurs at
the residue immediately following the conserved Lys-Ser-Gly
motif (15). By analogy with the structures of serine b-lactama-
ses and low-Mr PBPs, this motif is predicted to form a b-strand
along one side of the b-lactam-binding pocket of high-Mr PBPs
(15). Substitutions at this residue have not been found in the
PBPs of previously examined b-lactam-resistant clinical iso-
lates of S. pneumoniae, but the Thr-5503Ala substitution has
been found in PBP2x of laboratory mutants selected for in-
creased resistance to cefotaxime (19). Interestingly, the reverse
substitution at the corresponding residue occurs in some ex-
panded-spectrum serine b-lactamases (Ala-2373Thr) that
have an increased ability to hydrolyze (and an increased affinity
for) expanded-spectrum cephalosporins (6).
CS109 was 16-fold more resistant to penicillin than CS111.
CS109 and CS111 possessed different pbp2b genes, but the
resistance of CS111 to penicillin (MIC, 0.25 mg/ml) was not
limited by the affinity of PBP2b, since for transformants ex-
pressing this PBP, together with low-affinity forms of PBP1a
and -2x (R6CS109/2x/1a/CS111/2b), the MIC of benzylpenicillin was
1 mg/ml. The penicillin resistance of CS111 was, however, lim-
ited by the affinity of PBP2x. The ancestral pbp2x gene, and the
pbp2x gene of CS109, when combined with the pbp1a and
pbp2b genes from highly penicillin-resistant pneumococci, re-
sulted in transformants for which the MIC of benzylpenicillin
was 8 mg/ml (Table 3). However, the pbp2x gene from CS111
could provide resistance to ,0.25 mg/ml in the same genetic
background. As the ancestral pbp2x gene differed from that of
CS111 at only a single nucleotide site, the low level of penicillin
resistance of CS111 must be a consequence of the Thr-
5503Ala substitution in PBP2x.
The putative ancestral PBP2x, when expressed together with
highly b-lactam-resistant forms of PBP1a and/or PBP2b, could
result in transformants for which the MICs of cefotaxime and
benzylpenicillin are 8 mg/ml each, whereas PBP2x from CS111
resulted in transformants for which the MIC of cefotaxime was
32 mg/ml but the MIC of benzylpenicillin was#0.25 mg/ml. The
putative ancestral PBP2x appears therefore to have had very
low affinity for both penicillin and expanded-spectrum cepha-
losporins. The Thr-5503Ala substitution in CS111 further re-
duces the affinity of PBP2x for expanded-spectrum cephalo-
sporins but at the cost of a loss of its low affinity for penicillin.
Strains CS109 and CS111 appear to be very closely related
and possess identical pbp1a genes and almost identical pbp2x
genes. Their pbp2b genes are also identical, except that the
gene from CS109 contains an additional region of a highly
diverged sequence that has presumably been introduced by
an interspecies recombinational event. It seems likely that
CS109 and CS111 have arisen from a common ancestor that
possessed identical mosaic pbp1a, -2x, and -2b genes (Fig. 5).
The ancestor presumably possessed the pbp2b gene of CS111
and a pbp2x gene lacking the substitutions within codons 550
and 701. The MICs of benzylpenicillin and cefotaxime for
transformants of this type (R6ancestor/2x/CS111/1a/2b) were 1 and
8 mg/ml, respectively. In this scenario, CS111 would have arisen
by the introduction of the Thr-5503Ala substitution in PBP2x,
which provides increased resistance to expanded-spectrum
cephalosporins but a loss of resistance to penicillin. Con-
versely, CS109 would have arisen by an interspecies recombi-
national event that introduced an additional diverged region
into the pbp2b gene and by the Gly-7013Ser substitution in
PBP2x (Fig. 5). The pbp2b gene of CS109 provides greater
resistance to penicillin than that of CS111 (or the presumed
ancestral strain), and the recombinational event in pbp2b was
probably selected, as it further increases resistance to penicil-
lin. The selection pressure for the Gly-7013Ser substitution in
PBP2x of CS109 is unclear, as we were unable to detect any
effect of this change on resistance to benzylpenicillin or cefo-
taxime (or ampicillin, amoxicillin, oxacillin, or ceftriaxone).
Finally, our results demonstrate that point mutations as well
as recombinational events are important in the development of
resistance to b-lactam antibiotics in pneumococci. Since all of
the penicillin- or cephalosporin-resistant clinical isolates we
have examined possess mosaic pbp genes, we believe that the
initial steps in the emergence of resistance in pneumococci are
predominantly due to interspecies recombinational events (8).
However, as mosaic pbp genes that encode PBPs with de-
creased affinity for most (or all) b-lactam antibiotics have
emerged and are now common in several countries, it is likely
that further selection for resistance to penicillins or cephalo-
sporins, or to newly introduced b-lactams, will occur by the
introduction of point mutations in the preexisting pool of mo-
saic pbp genes to reduce further the affinity of these PBPs.
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